Eva-Lotta joined Immunocore as Chief Business Officer in May 2013. She has over 25 years of business development experience from the biotechnology and life science industry in both private and public companies, and is an elected member of the BioIndustry Association (BIA) Board of Directors. She is also on the Board of Targovax ASA. Eva-Lotta was previously at Ablynx NV, where she served as Chief Business Officer from 2006. Prior to Ablynx, Eva-Lotta served as Senior Director of Business Development and Site Operations (Europe) at Vertex Pharmaceuticals and before that held senior positions at Oxford Asymmetry International plc (now part of Evotec) and Oxford GlycoSystems. She received her degree in microbiology from the University of Stockholm.